Amarin Corporation plc (NASDAQ:AMRN) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET

Company Participants

Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Affairs

Karim Mikhail - President and Chief Executive Officer

Steve Ketchum - President, R&D and Chief Scientific Officer

Mike Kalb - Chief Financial Officer

Conference Call Participants

Louise Chen - Cantor

Roanna Ruiz - SVB Securities

Jessica Fye - JPMorgan

Paul Choi - Goldman Sachs

Operator

Welcome to Amarin Corporation’s Conference Call to discuss its First Quarter 2022 Financial Results and Operational Updates. This conference call is being recorded today, May 4, 2022. I would like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at Amarin.

Lisa DeFrancesco

Good morning, everyone and thank you for joining us. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. We may not achieve our goals, carryout our plans or intentions or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate.

For additional information concerning the factors that could cause our actual results to differ materially, please see the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2021 and our Form 10-Q for the quarter ended March 31, 2022, which have been filed with the SEC and are now available through the Investor Relations section of our website at www.amarincorp.com. We encourage everyone to read these documents. This call is intended for investors in Amarin and is not intended to promote the use of VASCEPA. An archive of this call will be posted on Amarin’s website in the Investor Relations section.

Karim Mikhail, Amarin’s President and Chief Executive Officer, will lead our discussion; Dr. Steve Ketchum, President of R&D and Chief Scientific Officer, will provide an update on our FTC program as well as recent clinical data and publications; and Mike Kalb, Amarin’s Chief Financial Officer, will provide a more detailed review of our first quarter 2022 financial results. After prepared remarks, we will open the call to your questions. I remind you that multiple audiences typically listen to calls of this nature, including existing investors, potential new investors, employees, current and potential collaborators and current and potential competitors. As always, in this call we will attempt to provide constructive information without compromising our competitive and strategic positioning.